Astrazeneca (AZN) Raw Materials (2015 - 2025)

Astrazeneca has reported Raw Materials for 11 years, with the latest figure at $1.9 billion in Q4 2025.

• On a quarterly basis, Raw Materials rose 24.71% year-over-year to $1.9 billion in Q4 2025; TTM through Dec 2025 was $1.9 billion, a 24.71% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 24.71% from the prior year.
• Raw Materials was $1.9 billion for Q4 2025 at Astrazeneca, up from $1.5 billion in the prior quarter.
• The five-year high for Raw Materials was $1.9 billion in Q4 2025, with the low at $1.4 billion in Q4 2022.
• Average Raw Materials over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Raw Materials jumped 39.06% in 2021, then retreated 18.97% in 2022.
• Over 5 years, Raw Materials stood at $1.8 billion in 2021, then declined by 18.97% to $1.4 billion in 2022, then gained by 7.67% to $1.5 billion in 2023, then declined by 2.74% to $1.5 billion in 2024, then climbed by 24.71% to $1.9 billion in 2025.
• The last three Raw Materials figures came in at $1.9 billion (Q4 2025), $1.5 billion (Q4 2024), and $1.5 billion (Q4 2023), per Business Quant data.